"We Are Undeniable": ALS Association Launches Campaign to Confront Insurance Denials

The ALS Association found that nearly all of 19 commercial insurers it reviewed impose coverage requirements for Qalsody that the FDA did not require, while about one-third do not cover it. The Association launched We Are Undeniable, offering families a free appeal-letter tool, guidance and pro bono legal help; its survey found about one in three respondents had an ALS-care claim or prior authorization denied. Appeals took up to six months, and about a third of requests remained denied or only partly approved.

Analysis

The market-relevant risk is precedent, not the immediate cost of covering ALS treatment: a narrow patient population is unlikely by itself to move payer earnings, but a successful campaign could weaken insurers’ ability to use non-label clinical criteria and prior-authorization friction across other rare-disease drugs. That would shift some economics toward manufacturers through higher access and utilization, while raising payer costs and reducing a tool for managing expensive therapies. The counterweight is that FDA approval does not itself establish broad coverage obligations; insurers may defend criteria as evidence-based, and this campaign is not evidence of a legal or regulatory change.

Near term, expect limited fundamental impact absent a named insurer, binding policy action, or measurable change in approvals. Over 1–3 months, watch for state or federal proposals, litigation, and insurer policy revisions; over 6–18 months, the larger signal would be whether appeal support and public scrutiny measurably improve access across rare-disease categories. The contrarian point: the issue may be financially immaterial for payers in isolation but underpriced as a source of broader utilization-policy precedent. No company-specific earnings or valuation conclusion is supportable from the information provided.

Key Decisions for Investors

• No immediate directional trade: the article provides neither insurer identities nor evidence of a change in coverage rates, utilization, or policy. Avoid treating advocacy activity alone as a payer-sector earnings catalyst.
• Set a watch item on the Qalsody manufacturer and rare-disease biotech exposure: verify prescription growth, payer access, and any company-reported reimbursement changes before considering a position.
• Monitor managed-care companies for published policy changes, appeal/denial metrics, and legal or legislative developments. A broad coverage mandate or a sustained rise in approvals would strengthen the negative payer / positive manufacturer read-through; no policy change and stable access data would weaken it.
• If payer stocks sell off on this campaign alone, assess the move against the small direct disease scope before adding exposure; reassess if the issue expands into binding rules or broader restrictions on prior authorization.